Frequency Therapeutics’ hearing loss treatment showed early signs of efficacy last year, with some patients showing improvements after a few months. Now, as the biotech plugs away at a phase 2a study, ...

Evidence of Durable Hearing Improvements in Follow-Up with Patients from Phase 1/2 Study; Speech Intelligibility and Audibility Sustained for Up to 21 Months After Initial Dosing Data Highlighted at ...

The U.S. Food and Drug Administration recently approved the first implantable device for people 18 and older with severe or profound sensorineural hearing loss of high-frequency sounds in both ears, ...

National Correspondent; Anchor, "CBS Weekend News" Jericka Duncan is a national correspondent and anchor of the "CBS Weekend News." She's based in New York City. Chris Sopuch has taught at Oakcrest ...

Feb. 13 (UPI) --Regenerative medicine company Frequency Therapeutics announced Monday it will scrap development of a drug called FX-322, after testing failed to show improvement in speech perception ...

An experimental regenerative therapy that Frequency Therapeutics was developing to treat a form of hearing loss has failed to beat a placebo in a clinical trial for the second time in two years, ...

Shape matters, even in hearing. Specifically, it is the shape of the cochlea – the snail-shell-shaped organ in the inner ear that converts sound waves into nerve impulses that the brain deciphers – ...